aestheticmedguideAestheticMedGuide
Devices

miraDry for underarm sweating: what the only permanent hyperhidrosis device actually does

miraDry is the only FDA-cleared device that permanently destroys underarm sweat glands with microwave energy. It is not for hands or feet, and the Botox comparison is not as simple as cost.

Ran Chen
Ran Chen
10 min read · Published · Evidence-based

Excessive underarm sweating — primary axillary hyperhidrosis — is a medical condition in which the sweat glands produce far more moisture than the body needs for temperature regulation, soaking through clothing regardless of temperature, stress level, or deodorant. It is common, it is diagnosable with a simple screening tool (the Hyperhidrosis Disease Severity Scale, HDSS), and for most of medicine's history its only durable solution was destructive surgery. That changed in 2011, when the FDA cleared miraDry, a microwave device that permanently destroys underarm sweat glands without an incision. It remains the only device cleared specifically to permanently reduce underarm sweating and odor.

This article covers what miraDry does and does not do, how its durability compares to botulinum toxin injections (covered in detail in our Botox for hyperhidrosis guide), what the procedure and recovery actually feel like, and who is — and is not — a candidate. It is educational and not a substitute for evaluation by a qualified clinician. The headline to keep in mind is the one most marketing leaves out: miraDry is cleared for underarms only, and it is positioned by insurers and dermatology guidelines as a third-line option after topical antiperspirants and botulinum toxin, not a first stop.

How miraDry works — and the anatomic trick that makes it possible

miraDry delivers microwave energy at 5.8 GHz through a handpiece held against the underarm. The clever part is the physics: the system is designed to focus heating at the dermal–fat interface, the depth at which the sweat glands live, while a continuous surface-cooling system protects the overlying skin from burning. At that target depth the energy produces thermolysis — heat destruction — of the eccrine and apocrine glands. Because adult sweat glands do not regenerate, the destruction is permanent. The same energy also damages the hair follicles and odor glands in the field, which is why patients typically see reductions in underarm hair and odor alongside the reduction in sweat.

The procedure is done in an office setting under local (tumescent) anesthesia — a large volume of dilute lidocaine and adrenaline injected into each underarm, both for pain control and to create a fluid buffer that further protects deeper tissue. A full treatment is roughly an hour per underarm, and the original protocol calls for two sessions spaced roughly three months apart, though some practices now offer a single high-energy session.

What the evidence shows for efficacy

The pivotal data come from Hong and colleagues' industry-sponsored case series (31 patients with severe baseline HDSS), in which 90% saw their HDSS score drop to 1 or 2 (mild) at both 6 and 12 months after treatment, and from longer-term follow-up showing durability at 12 months and beyond. A more recent direct head-to-head randomized trial (Copenhagen, 2021–2023) compared miraDry to botulinum toxin A and found microwave thermolysis effective for reducing axillary sweating and odor, with the expected durability advantage of a destructive versus a reversible modality. Across the literature, microwave therapy reliably lowered HDSS scores by at least one level, with average sweat reduction reported in the 80% range at 12 months and lasting odor reduction in a large majority of patients.

Two honest caveats belong next to those numbers. First, the evidence base is tilted toward industry-sponsored series and a limited number of randomized trials; reviewers have consistently called for larger, longer, independent RCTs. Second, "permanent reduction" is not "zero sweat." Most patients are dramatically improved, not bone-dry, and a meaningful minority need a touch-up or third session. Before any third treatment, a clinician should run a starch-iodine test to map exactly where residual sweating originates, so the extra session targets the remaining glands rather than treating the whole underarm again.

Side effects and recovery

miraDry is generally well tolerated but has a real recovery period that patients should plan for. The most common adverse events are localized and temporary: swelling, soreness, and bruising of the underarm for several days to a couple of weeks; altered sensation or numbness (reported in roughly two-thirds of patients in one series, with a median duration of about five weeks); and palpable bumps under the skin (a similar share, median duration around six weeks) as the destroyed gland tissue is reabsorbed. Underarm hair loss in the treatment field is expected. Most patients return to work the next day but avoid exercise and heavy arm use for a few days. The surface cooling keeps full-thickness burns rare, but they are a recognized risk — which is part of why the device is meant to be operated by trained clinicians with proper anesthesia and technique.

One realistic timeline detail that sets expectations: it is normal to be completely dry immediately after treatment, with some sweating returning at two to three weeks as post-treatment swelling resolves — the durable reduction is measured from there, not from the first dry day. Serious complications are uncommon, but worth naming honestly: as with any procedure that breaks skin and creates a thermal injury, infection is a risk, and rare severe cases (including a published case of necrotizing fasciitis) underscore why sterile technique and prompt follow-up for spreading pain, fever, or redness matter. If you experience sustained fever or worsening pain after treatment, that is a reason to contact the provider urgently, not wait it out.

A common worry — "if you destroy sweat glands, does the body over-sweat elsewhere?" — has a reassuring answer backed by anatomy and the evidence so far. The underarms hold less than 2% of the body's sweat glands, so eliminating them has no meaningful effect on whole-body temperature regulation, and the compensatory sweating seen after endoscopic thoracic sympathectomy has not been shown to be a concern with miraDry. This is one of the cleaner distinctions between miraDry and the surgical option further down the ladder.

miraDry vs. botulinum toxin — the real comparison

The decision most patients face is between miraDry and botulinum toxin injections. They work by entirely different mechanisms and have genuinely different cost-and-durability profiles:

  • Botulinum toxin (Botox and other onabotulinum/abobotulinum formulations) was FDA-approved for severe primary axillary hyperhidrosis in 2004. It temporarily blocks the nerve signals that switch the sweat glands on, reducing sweat production dramatically — but it wears off, typically every four to six months, and must be repeated indefinitely to maintain the effect.
  • miraDry destroys the glands outright, so the result is meant to be permanent after one or two sessions, with no ongoing treatment required.

The trade is upfront cost and recovery (miraDry) versus lower per-treatment cost but lifetime repetition (toxin). A representative cash figure for a miraDry course lands in the low thousands; a single botulinum toxin treatment is typically less but recurs several times a year forever. Over a multi-year horizon, the economics can favor miraDry for a patient certain they want permanent underarm resolution — but only if they are an appropriate candidate and only for the underarms.

What miraDry cannot do — and who is not a candidate

The limits are as important as the benefits:

  • Underarms only. The device is FDA-cleared for primary axillary hyperhidrosis. It is not cleared for the hands, feet, face, or generalized sweating. Patients whose main burden is palmar or plantar need a different approach (iontophoresis, botulinum toxin, or in refractory cases sympathetic surgery).
  • Not for secondary hyperhidrosis. miraDry is for primary (idiopathic) hyperhidrosis. Sweating driven by an underlying cause — thyroid disease, infection, a medication, a tumor — requires diagnosis and treatment of the cause, not gland destruction.
  • Not first-line per most coverage guidelines. Insurer and dermatology coverage policies generally position miraDry as a third-line option, after a prescription-strength topical antiperspirant (typically aluminum chloride) and botulinum toxin have been tried and failed or were not tolerated. Patients who want insurance to share the cost should expect to document those prior steps; many cash-pay practices will treat directly.
  • Pregnancy, active infection, and implanted electronic devices in or near the treatment field are typical contraindications and precautions to discuss with the provider.

The wider hyperhidrosis ladder

miraDry sits inside a broader treatment ladder worth knowing: prescription topical antiperspirants first; botulinum toxin injections for the underarms (and other focal areas); iontophoresis (a mild electrical-current water bath) for the hands and feet; topical glycopyrrolate and oral anticholinergics (glycopyrrolate, oxybutynin) for more generalized sweating; and, as a last-resort surgical option, endoscopic thoracic sympathectomy (ETS), which carries serious and sometimes permanent compensatory-sweating risk and is rarely the right answer. The point of the ladder is that the right treatment depends on where you sweat and why — which is exactly why "miraDry for hyperhidrosis" is really "miraDry for underarm hyperhidrosis."

What it costs

miraDry is typically sold as a cash-pay aesthetic procedure, with a full course (one or two sessions) commonly priced around $3,000 — the International Hyperhidrosis Society's ballpark figure — varying meaningfully by region and practice. Insurance coverage is possible but usually requires documented failure of topical antiperspirants and botulinum toxin, and policies vary widely. Botulinum toxin for hyperhidrosis, by contrast, is better-established with insurers and may be covered for severe axillary disease, though it still recurs several times a year. The number to compare is the multi-year all-in cost of repeated toxin treatments versus a single miraDry course — not the per-session headline.

What to ask a provider

  • Is my sweating primary axillary hyperhidrosis, and have we ruled out a secondary cause? Gland destruction only makes sense for primary disease.
  • Have we actually tried a prescription antiperspirant and/or botulinum toxin first? Coverage policies and good practice both favor it.
  • Will I need one session or two, and what is the all-in price? Single high-energy sessions exist; clarify what you are paying for.
  • What is the recovery, realistically? Plan for swelling, soreness, altered sensation, and bumps lasting days to weeks.
  • What happens if I am under-treated — is a touch-up included or extra?
  • If my main problem is my hands or feet, what is my right option instead? A credible answer redirects to iontophoresis or botulinum toxin rather than pushing miraDry.

For the right patient — severe primary underarm sweating, realistic about recovery, and weighing the cost of lifetime toxin repetition against a single destructive course — miraDry is a genuinely useful and durable option. It is not, despite the marketing, a universal hyperhidrosis fix, and the patients who get burned (metaphorically) are the ones who were never appropriate candidates to begin with.

Sources

Topics
SafetyCostRegulatory
Ran Chen
Contributing Editor
Ran Chen

Founder, AestheticMedGuide. Life-sciences operator covering aesthetic devices, injectables, and the industry behind them. Previously global market-access lead across pharma and medtech.

Follow on LinkedIn →

Keep reading from Devices

See all →
Skin · 11 min read

Alopecia areata treatment: JAK inhibitors, steroids, and what regrowth actually looks like

Alopecia areata is autoimmune hair loss, not pattern baldness. Three FDA-approved JAK inhibitors (Olumiant, Litfulo, Leqselvi) finally treat severe…

Injectables · 12 min read

How to Verify Dermal Filler Legitimacy in Hong Kong: Clinic Vetting and Product Red Flags

Hong Kong's GN-00 update classifies dermal fillers as medical devices. Here is how to verify product authenticity, vet clinics, and spot red flags…

Skin · 11 min read

Vitiligo treatment: Opzelura, light therapy, and surgery for repigmentation

Vitiligo is an autoimmune loss of pigment. The 2022 FDA approval of Opzelura (ruxolitinib) made it the first repigmentation drug — used alongside…